ライフサイエンスコーパス: FK506-binding protein

1 o interact with Cnb1p, calmodulin, or Fkb1p (FK506-binding protein).

2 nd channels deficient in immunophilin 12-kDa FK506-binding protein.

3 e developed through directed evolution of an FK506-binding protein.

4 is in many ways an exceptional member of the FK506-binding proteins.

5 iphosphate-binding cassette transporters and FK506-binding proteins.

6 reported that loss-of-function mutations in FK506 Binding Protein 10 (FKBP10) lead to skeletal defor

7 FK506-binding protein 10 (FKBP10) is a collagen chaperon

8 Loss of function mutations in FK506-binding protein 10 (FKBP10), encoding the FKBP65 p

9 entrapped in the core of ELP nanoparticles, FK506 binding protein 12 (FKBP), which is the cognate pr

10 in binds intracellularly to the immunophilin FK506 binding protein 12 (FKBP12), and the resultant com

11 t to tacrolimus, indolyl-ASC binds poorly to FK506 binding protein 12 (FKBP12), the major cytosolic r

12 in mice in the context of rapamycin-induced FK506 binding protein 12 (FKBP12)-FKBP12 rapamycin bindi

13 ated hearts from mutant embryos deficient in FK506 binding protein 12 (FKBP12).

14 onserved sequence in the alpha4 helix of the FK506 binding protein 12 (FKBP12)/rapamycin-binding (FRB

15 h genotype shows similar expression of RyR1, FK506 binding protein 12 kDa, and Ca(2+)-ATPase, but RyR

16 Dissociation of the small FK506 binding protein 12 subunit (FKBP12) increases RyR1

17 FKBP12 (FK506 binding protein 12) is a prolyl cis-trans isomeras

18 th are increased, and association of RyR2 by FK506 binding protein 12.6 (FKBP12.6) is decreased in PA

19 Calstabin2, also named FK506 binding protein 12.6 (FKBP12.6), is a subunit of r

20 oform (RyR1) interaction with calmodulin and FK506 binding protein 12.6.

21 N-dependent transcription factor family, and FK506 binding protein 12/12.6 (FKBP12/12.6), effectors o

22 FK506 binding proteins 12 and 12.6 (FKBP12 and FKBP12.6)

23 the kinase mammalian target of rapamycin and FK506-binding protein 12 (FKBP), respectively, the optim

24 cross-linkable form of clathrin by using an FK506-binding protein 12 (FKBP)-clathrin fusion protein

25 tes to BCR-mediated lytic induction and that FK506-binding protein 12 (FKBP12) binding alone is not a

26 FK506-binding protein 12 (FKBP12) binds the immunosuppre

27 The FK506-binding protein 12 (FKBP12) is a cytoplasmic prote

28 A series of mutations to FK506-binding protein 12 (FKBP12) were designed to vary

29 u-Pro substitutions prevent interaction with FK506-binding protein 12 (FKBP12), whose putative functi

30 inding of RAPA to its intracellular receptor FK506-binding protein 12 (FKBP12).

31 th factor (PDGF) beta receptors fused to the FK506-binding protein 12 (FKBP12).

32 n transgenic plants deficient in Arabidopsis FK506-binding protein 12 (FKP12), whereas FKP12 overexpr

33 for the small molecule synthetic ligand for FK506-binding protein 12 (SLF).

34 a(2+) channel (dihydropyridine receptor) and FK506-binding protein 12 as well as in "hot spot" region

35 MTB, and several accessory subunits such as FK506-BINDING PROTEIN 12 KD INTERACTING PROTEIN 37KD (FI

36 rane domain of HMGR fused to three copies of FK506-binding protein 12, we were able to induce oligome

37 labeled CaM binding near donor-labeled FKBP (FK506-binding protein 12.6) on the cytoplasmic domain of

38 we found that hippocampal overexpression of FK506-binding protein 12.6/1b (FKBP1b), a negative regul

39 Hippocampal overexpression of FK506-binding protein 12.6/1b (FKBP1b), a negative regul

40 e found that expression of the gene encoding FK506-binding protein 12.6/1b (FKBP1b), a small immunoph

41 Recently, we found that FK506-binding protein 12.6/1b (FKBP1b), a small protein

42 , including skeletal triadin, calsequestrin, FK506-binding protein, 12 kD, sarco(endo)plasmic reticul

43 In vitro, GPI-1046 bound to FK506 binding protein-12 and elicited neurite outgrowth

44 C bound about 10 times less to intracellular FK506 binding protein-12 than tacrolimus or ASC.

45 T cells through formation of a complex with FK506 binding protein-12, which inhibits the phosphatase

46 Phosphatidic acid (PA) interacts with the FK506-binding protein-12-rapamycin-binding (FRB) domain

47 ptor type 2A/2B, SMAD family member 1/5, and FK506-binding protein 12kD.

48 e N-terminal region (amino acids 1-331) with FK506-binding protein 13 (FKBP13).

49 In cardiomyocytes, FK506-binding protein 1b/12.6 (FKBP1b) binds and stabili

50 utations in the FKBP14 gene encoding FKBP22 (FK506 Binding Protein 22 kDa) cause kyphoscoliotic Ehler

51 We previously identified the FK506 binding protein 38 (FKBP38) as a negative regulato

52 that PA competes with the mTORC1 inhibitor, FK506 binding protein 38 (FKBP38), for mTOR binding at a

53 FK506-binding protein 38 (FKBP38), a membrane-anchored,

54 FKBP4, encoding the immunophilin FK506-binding protein 4, was identified as a plausible c

55 ocaust survivors showed lower methylation of FK506 binding protein 5 (FKBP5) intron 7, site 6 compare

56 FK506 binding protein 5 (FKBP5) is a co-chaperone that i

57 ine methylation within the gene encoding for FK506 binding protein 5 (FKBP5) was measured in Holocaus

58 ved in regulating the stress system, such as FK506 binding protein 5 (FKBP5), interact with early-lif

59 ion, we examined two genes (prodynorphin and FK506 binding protein 5) that are strongly regulated by

60 The gene FK506 binding protein 5, FKBP5, is a critical regulator

61 ding of Raf1-tr to the cytoplasmic chaperone FK506 binding protein 5.

62 ylase, brain-derived neurotrophic factor and FK506 binding protein 5.

63 the downregulation of FKBP5 (encoding FKBP5 [FK506 binding protein 5]).

64 f microRNA (miRNA) expression related to the FK506-binding protein 5 (FKBP5) gene may contribute to t

65 e response regions of progesterone-regulated FK506-binding protein 5 (FKBP5) immunophilin and small R

66 evels of the glucocorticoid-responsive genes FK506-binding protein 5 (Fkbp5), Period 1 (Per1), and se

67 lves the interaction of IFI44L with cellular FK506-binding protein 5 (FKBP5), which in turn interacts

68 Corticosteroid-mediated transactivation (FK506-binding protein 5 induction by FLU) increased in t

69 or alpha and corticosteroid transactivation (FK506-binding protein 5) and transrepression markers (IL

70 The FKBP5 gene codes for a co-chaperone, FK506-binding protein 5, that exerts negative feedback o

71 The FK506 binding protein 51 (FKBP5) is a negative regulator

72 Single nucleotide polymorphisms of the FK506 binding protein 51 (FKBP51) gene have been repeate

73 d that the suggested psychiatric risk factor FK506 binding protein 51 (FKBP51) increases phosphorylat

74 FK506 binding protein 51 (FKBP51, also called FKBP5) bel

75 f selected stress-response-associated genes (FK506 binding protein 51 [FKBP5], glucocorticoid recepto

76 FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5)

77 eased the relative association of Hsp90 with FK506 binding protein 51 versus FK506 binding protein 52

78 PTSD/AUD to evaluate compounds that inhibit FK506-binding protein 51 (FKBP5), a co-chaperone modulat

79 FK506-binding protein 51 (FKBP5), a cochaperone protein,

80 portant modulator of stress responses is the FK506-binding protein 51 (FKBP5/FKBP51).

81 The FK506-binding protein 51 (FKBP51) emerged as a key playe

82 ss-related disorders are linked to increased FK506-binding protein 51 (FKBP51) expression levels in t

83 The FK506-binding protein 51 (FKBP51) is a key regulator of

84 The FK506-binding protein 51 (FKBP51) is a promising drug ta

85 FK506-binding protein 51 (FKBP51) is gaining increased r

86 The immunophilin FK506-binding protein 51 (FKBP51), in conjunction with t

87 enes and ESTs, delta-sarcoglycan, myosin Va, FK506-binding protein 51 (FKBP51), the potassium channel

88 In the quest for lead-like ligands for the FK506-binding protein 51 (FKBP51), we designed two new c

89 Here, we show that the Hsp90 cochaperone, FK506-binding protein 51 (FKBP51), which possesses both

90 enes and markedly up-regulated expression of FK506-binding protein 51 (FKBP51).

91 ic antigen, transmembrane protease serine 2, FK506-binding protein 51 and fatty acid synthase.

92 FK506-binding protein 51 is involved in hypothalamic-pit

93 phagy via the stress-responsive co-chaperone FK506-binding protein 51.

94 ocorticoid-induced leucine zipper (GILZ) and FK506 binding protein-51 (FKBP51)].

95 f Hsp90 with FK506 binding protein 51 versus FK506 binding protein 52 and inhibited hormone-induced G

96 Immunophilin FK506-binding protein 52 (FKBP52) is a cochaperone that

97 FK506-binding protein 52 (FKBP52) is an immunophilin tha

98 the immunosuppressant drug FK506, termed the FK506-binding protein 52 (FKBP52).

99 es that form complexes with caveolin-1, i.e. FK506-binding protein 52, cyclophilin A, and cyclophilin

100 own that male mice with targeted ablation of FK506-binding protein-52 (Fkbp52) develop hypospadias, m

101 ations in lysyl hydroxylase 2 (LH2/PLOD2) or FK506 binding protein 65 (FKBP65/FKBP10).

102 roxylase 2 (LH2) and its molecular chaperone FK506-binding protein 65 were both significantly increas

103 Heat shock protein 47 (HSP47) and FK506-binding protein-65 (FKBP65) defects cause types X

104 Here we focus on the role of FK506-binding protein 8 (FKBP8) in controlling neural ce

105 We have now examined the role of FK506-binding protein 8 (FKBP8), a component of the CFTR

106 protein 90 (Hsp90)-associated co-chaperones: FK506-binding protein 8 (FKBP8), activator of Hsp90 ATPa

107 how that the immunophilin FKBP12, the 12-kDa FK506-binding protein (also known as FKBP prolyl isomera

108 sensitive pathway, which includes the 12-kDa FK506 binding protein and includes rapamycin and the 12-

109 FK1012-induced dimerization of GFP fused to FK506-binding protein and clustering of glycosylphosphat

110 Rapamycin, which forms a complex with FK506-binding protein and FK506-binding protein-rapamyci

111 control of rapamycin-induced dimerization of FK506-binding protein and FKBP12-rapamycin-binding prote

112 trin), and Ca2+ release (ryanodine receptor, FK506-binding protein and junctin) during excitation-con

113 ch induces a tight association between FKBP (FK506-binding protein) and FRAP (FKBP-rapamycin-associat

114 t into two moieties that were fused to FKBP (FK506-binding protein) and FRB (rapamycin-binding domain

115 perativity can be affected by the binding of FK506 binding protein, and hence, modulated by adrenergi

116 ting of an invariant ligand that targets the FK506-binding protein (AP1867) attached to 320 substitut

117 ains a domain similar to that found in other FK506-binding proteins, ARA9 binding to 3H-FK506 could n

118 mplex including calstabin (formerly known as FK506-binding protein), calmodulin, phosphodiesterase, k

119 f cooperativity, regulated by the binding of FK506 binding-protein, can have a dramatic effect on the

120 gh-resolution X-ray structures of ubiquitin, FK506-binding protein, chymotrypsin inhibitor 2, and rub

121 rapamycin, indicating a member of the FKBP (FK506-binding protein) class.

122 S107 (a stabilizer of RyR1-FK506 binding protein coupling that reduces Ca(2+) leak)

123 ing the signaling domain of Mpl linked to an FK506 binding protein domain (to permit dimerization by

124 Like immunophilins, Shut-down contains an FK506-binding protein domain and a tetratricopeptide rep

125 AIPL1 and PDE6 are known to interact via the FK506-binding protein domain of AIPL1, the contribution

126 a by dimerizing rapamycin-binding domain and FK506-binding protein domains that are attached to ciste

127 romosomal damage and a critical function for FK506 binding proteins during meiosis.

128 d a chimeric receptor composed of a modified FK506-binding protein (F36V) fused with the fibroblast g

129 the proline isomerase Fpr4, a member of the FK506 binding protein family in Saccharomyces cerevisiae

130 peptidyl-prolyl cis/trans-isomerases of the FK506-binding protein family and may be involved in fold

131 We show that a member of the FK506-binding protein family, FKBP8, is an essential ant

132 se AIP exhibits homology with members of the FK506-binding protein family.

133 lin production, whereas the immunomodulatory FK506 binding protein (FK506BP) was up-regulated.

134 Cyclophilin and FK506 binding protein (FKBP) accelerate cis-trans peptid

135 ocytes, we expressed a fusion protein of the FK506 binding protein (FKBP) and caspase 8 under control

136 rapamycin-inducible interaction between the FK506 binding protein (FKBP) and the FKBP-rapamycin bind

137 The FK506 binding protein (FKBP) family of proteins provide

138 ch signaling domain was incorporated into an FK506 binding protein (FKBP) fusion to allow for its spe

139 orresponding with the entire sequence of the FK506 binding protein (FKBP) has been investigated in aq

140 a modified human caspase 9 fused to a human FK506 binding protein (FKBP) to allow conditional dimeri

141 omerizing proteins engineered to contain the FK506 binding protein (FKBP), to trigger Fas via FKBP-li

142 Expression of FK506 binding protein (FKBP)-clathrin light chain chimer

143 Our data revealed that both the FK506 binding protein (FKBP)-like domain and the tetratr

144 e of 3247 small molecules for binding to the FK506 binding protein (FKBP).

145 of fragments against the active sites of the FK506 binding protein (FKBP-12) and HIV-1 aspartyl prote

146 s responsible for primary recognition by the FK506 binding protein (FKBP-12), along with a diverse re

147 ted the molecular events associated with the FK506 binding proteins (FKBP) -52 and -51 response to co

148 y bind to the same set of immunophilins, the FK506 binding proteins (FKBP).

149 )-2alpha as well as high-level expression of FK506-binding protein (FKBP) 12 by HGA.

150 vated splenic T lymphocytes deficient in the FK506-binding protein (FKBP) 12, a target of rapamycin a

151 ically inactive Cas9 (dCas9) in complex with FK506-binding protein (FKBP) and a CEM consisting of FK5

152 imerization system composed of the canonical FK506-binding protein (FKBP) and circular permutants of

153 hia coli as fusions to the C-terminus of the FK506-binding protein (FKBP) and purified from freeze-th

154 (also identified as FKBP52), a member of the FK506-binding protein (FKBP) class of immunophilins, was

155 This methodology relies on a mutated FK506-binding protein (FKBP) destabilizing domain (dd) f

156 In addition, the FK506-binding protein (FKBP) domain of AIPL1 encloses a

157 Typically, FK506-binding protein (FKBP) domains are fused to a sign

158 chimeric PECAM-1 cDNAs containing one or two FK506-binding protein (FKBP) domains at their COOH termi

159 The FK506-binding protein (FKBP) family of peptidyl-prolyl i

160 Members of the FK506-binding protein (FKBP) family regulate a range of

161 gulates mTOR through FKBP38, a member of the FK506-binding protein (FKBP) family that is structurally

162 Mips are part of the FK506-binding protein (FKBP) family, whose members typic

163 In addition, their complexes with the 12-kDa FK506-binding protein (FKBP) form more stable complexes

164 We constructed an AblNuk-FK506-binding protein (FKBP) fusion protein to enforce t

165 Dimerization of a TRH receptor-FK506-binding protein (FKBP) fusion protein was stimulat

166 , a cell-permeable molecule used to dimerize FK506-binding protein (FKBP) fusion proteins and initiat

167 The FK506-binding protein (FKBP) is an important regulator o

168 between five single-cysteine variants of the FK506-binding protein (FKBP) labeled with a donor probe,

169 For example, a cell-permeable, bivalent FK506-binding protein (FKBP) ligand stimulated clusterin

170 the chemically inducible dimerization domain FK506-binding protein (FKBP) or to the hexameric protein

171 on, in which they form binary complexes with FK506-binding protein (FKBP) through a shared FKBP-bindi

172 chimeric molecule by fusing a domain of the FK506-binding protein (FKBP) to the C terminus of APP.

173 Furthermore, fusion of a FK506-binding protein (FKBP) to the N terminus of human

174 el activity is modulated by interaction with FK506-binding protein (FKBP), and disruption of the RyR-

175 asmic reticulum membranes with a fluorescent FK506-binding protein (FKBP), and FRET was determined fo

176 mmunophilin receptors, cyclophilin (CyP) and FK506-binding protein (FKBP), respectively.

177 This study was intended to examine whether FK506-binding protein (FKBP), which is tightly associate

178 the scattering data features two independent FK506-binding protein (FKBP)-like and tetratricopeptide

179 The rapamycin and FK506-binding protein (FKBP)-target 1 (RAFT1, also known

180 ity for the abundant, cytoplasmic chaperone, FK506-binding protein (FKBP).

181 Fas intracellular domain, and 2 copies of an FK506-binding protein (FKBP).

182 how that the SPRY1 domain is located next to FK506-binding protein (FKBP).

183 and with FRET measurements involving RyR and FK506-binding protein (FKBP).

184 The FK506-binding proteins (FKBP) 51 and 52 are cochaperones

185 FK506-binding proteins (FKBP) 51 and 52 are cochaperones

186 FK506-binding proteins (FKBP) are immunophilins that int

187 containing synthetic ligand binding domains (FK506-binding protein [FKBP] or FKBP-rapamycin-binding d

188 CID tools such as the FK506-binding protein-FKBP-rapamycin-binding- (FKBP-FRB)

189 Here we show that the C.albicans FK506 binding protein FKBP12 homolog is required for FK5

190 Raf kinase activity, sequences encoding the FK506-binding protein FKBP12 were fused to the amino ter

191 e Ca(2+) channel CaV1.1, calmodulin, and the FK506-binding protein FKBP12, as well as in "hot spot" r

192 ene encoding a fusion protein containing the FK506-binding protein FKBP12, fused to the intracellular

193 ain, has been determined in complex with the FK506-binding protein FKBP12.

194 ncrease) and unaltered RyR2 affinity for the FK506-binding protein FKBP12.6 (Kd~0.8 nmol/L).

195 FK506-binding proteins FKBP12.6 and FKBP12 are associate

196 of fusion proteins, with c-Kit linked to the FK506 binding protein (FKBP12) and Flt-3 linked to the F

197 : green fluorescent protein (GFP) fused with FK506 binding protein (FKBP12) and GFP fused with the an

198 e cytoplasmic scaffold domain, including the FK506 binding protein (FKBP12) and PKA.

199 The 12 kDa FK506 binding protein (FKBP12) mediates the action of bo

200 lution-phase properties of six inhibitors of FK506 binding protein (FKBP12) were investigated using f

201 Members of this family, and notably FK506 binding protein (FKBP12), are thought to be involv

202 Because MIS releases FK506 binding protein (FKBP12), which activates the mamm

203 PKA-hyperphosphorylated and depleted of the FK506 binding protein (FKBP12).

204 65,000-dalton RyR1s, each of which binds one FK506 binding protein (FKBP12).

205 The FK506 binding protein (FKBP12.6) stabilizes RyR2, preven

206 ing." Removal of the regulatory subunit, the FK506 binding protein (FKBP12.6), functionally but not p

207 four type 2 RyR polypeptides (RyR2) and four FK506 binding proteins (FKBP12.6).

208 nosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-as

209 The 12 kDa FK506-binding protein (FKBP12) constitutively binds to t

210 (CnB) subunits complexed with FK506 and the FK506-binding protein (FKBP12) from human fungal pathoge

211 One chimera consists of a FK506-binding protein (FKBP12) fused to a cellular 'addr

212 FK506-binding protein (FKBP12) has been found to be asso

213 The FK506-binding protein (FKBP12) is important in the immun

214 n-mediated interaction of the human proteins FK506-binding protein (FKBP12) rapamycin-binding domain

215 ependent interaction between calcineurin and FK506-binding protein (FKBP12), an accessory subunit of

216 dulatory ligands, calmodulin (CaM) or 12-kDa FK506-binding protein (FKBP12), have been characterized

217 WDB002, in complex with the FK506-binding protein (FKBP12), potently and selectively

218 peptidyl-propyl isomerases cyclophilin A and FK506-binding protein (FKBP12), respectively, block cyto

219 onstants were determined for those amides of FK506-binding protein (FKBP12), ubiquitin, and chymotryp

220 dependent on its interaction with the 12-kDa FK506-binding protein (FKBP12).

221 on of the 12-kDa cis-trans proline isomerase FK506-binding protein (FKBP12).

222 phatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12).

223 Calmodulin (CaM) and FK506-binding protein (FKBP12.6) bind to RyR2 and stabil

224 o directly disrupt the binding of a 12.6-kDa FK506-binding protein (FKBP12.6) to RyR2, causing a RyR2

225 This study investigated the function of FK506-binding protein (FKBP12.6) using adenoviral-mediat

226 inds predominantly a 12.6-kDa isoform of the FK506-binding protein (FKBP12.6), whereas RyR2 from othe

227 The 12-kDa FK506-binding proteins (FKBP12 and FKBP12.6) are regulat

228 ternae (TC) contains four tightly associated FK506-binding proteins (FKBP12).

229 phorylation and depletion of the stabilizing FK506 binding protein, FKBP12.6.

230 The FK506-binding protein, FKBP12, is a putative target of t

231 t involving an endogenous ER-localized 13-kD FK506 binding protein (FKBP13) competing with the FKBP12

232 d shield-1 (S1), AgDD, an engineered variant FK506-binding protein (FKBP1A), rapidly (t (1/2) ~5 min)

233 and bronchial epithelial gene expression of FK506 binding protein (FKBP5), an indicator of steroid r

234 ucocorticoid receptors (GRs), and (4) 51 kDa FK506-binding protein (FKBP5).

235 The large FK506-binding protein FKBP52 has been characterized as a

236 The 52 kDa FK506 binding protein (FKBP52) is an important positive

237 Because ARA9 closely resembles the 52-kDa FK506-binding protein (FKBP52), found in the unliganded

238 the immunosuppressant drug FK506, termed the FK506-binding protein (FKBP52), interacts with the singl

239 identical to the Drosophila homolog of human FK506-binding protein, FKBP52 (previously known as FKBP5

240 shock protein 47 (Hsp47/SERPINH1) and 65-kDa FK506-binding protein (FKBP65/FKBP10), have been shown t

241 The cyclophilins and FK506 binding proteins (FKBPs) bind to cyclosporin A, FK

242 e of each immunophilin family, cyclophilins, FK506 binding proteins (FKBPs), and parvulins in bacteri

243 FKBP5) belongs to a family of immunophilins, FK506 binding proteins (FKBPs).

244 family of intracellular receptors termed the FK506 binding proteins (FKBPs).

245 omerases have been identified: cyclophilins, FK506-binding proteins (FKBPs) and parvulins.

246 FK506-binding proteins (FKBPs) are cellular receptors fo

247 FK506-binding proteins (FKBPs) are peptidyl-prolyl cis/t

248 some amino acid sequence similarity to human FK506-binding proteins (FKBPs) in residues 166 to 252 lo

249 FK506-binding proteins (FKBPs) represent one of the thre

250 Immunophilins, including FK506-binding proteins (FKBPs), are protein chaperones w

251 ) are a chaperone superfamily comprising the FK506-binding proteins (FKBPs), cyclophilins, and parvul

252 losporin-binding cyclophilins (CyPs) and the FK506-binding proteins (FKBPs).

253 The RyRs are physically associated with FK506-binding proteins (FKBPs); immunophilins, with cis-

254 These proteins include calstabins [FK506-binding proteins (FKBPs)], calmodulin (CaM), phosp

255 eric FK506 analog that binds to the attached FK506-binding proteins, FKBPs.

256 ll chaperones Hsp90, Hsp70, cyclophilins and FK506-binding proteins for cytosolic PTS1-uptake is demo

257 the immunophilin family of proteins, and the FK506-binding proteins form the FKBP subfamily of immuno

258 Here, we show that the FK506 binding protein Fpr3 prevents premature adaptation

259 yR1 and Ser-2809 in RyR2 and dissociation of FK506-binding proteins from the receptors have been impl

260 eby a chimeric PrP(C) composed of a modified FK506-binding protein (Fv) fused with PrP(C) and termed

261 domain) was fused with a cDNA for a modified FK506-binding protein, Fv (Fv-SLK 1-373).

262 Some FKBPs, notably FKBP12 (the 12-kDa FK506-binding protein), have defined roles in regulating

263 he folding pathway of human FKBP12, a 12 kDa FK506-binding protein (immunophilin), has been character

264 ls by affinity chromatography using 12.6-kDa FK506-binding protein in the form of a GST fusion as the

265 erization of PLU via fusion to either GST or FK506 binding protein (in the presence of dimerizing age

266 the immunophilins, cyclophilin A, and 12-kDa FK506-binding protein, in resting human Jurkat T cells.

267 Through insertion of a modified FK506 binding protein (insertable FKBP12, iFKBP) into th

268 mall-molecule drug discovery, as engineering FK506-binding protein into intracellular sites within Ca

269 The discovery that FK506 binding protein is a steroid binding protein may b

270 The recognition protein (FK506 binding protein) is inserted into functionally-ina

271 FKBP65 (65-kDa FK506-binding protein) is a member of the highly conserv

272 FKBP12, the 12-kDa FK506-binding protein, is a ubiquitous abundant protein

273 amino acid sequence similarity to the 52-kDa FK506-binding protein known to be associated with the gl

274 til a small molecule displaces them from the FK506-binding protein ligand-binding site.

275 romosome 6p21.3 at TNXB (tenascin XB)-FKBPL (FK506 binding protein like) [rs12153855/rs9391734; disco

276 ion between a novel anti-angiogenic protein, FK506-binding protein like (FKBPL), and these diseases.

277 MIPs share an FKBP (FK506 binding protein)-like prolyl-cis/trans-isomerase d

278 FK506-binding protein-like (FKBPL) has previously been s

279 the channel-stabilizing subunit calstabin2 (FK506-binding protein or FKBP12.6) causes SR Ca2+ leak i

280 The FK506-binding protein PfFKBP35 has gained attention as a

281 FKBP53 is one of the seven multi-domain FK506-binding proteins present in Arabidopsis thaliana,

282 rms a complex with FK506-binding protein and FK506-binding protein-rapamycin-associated protein, indu

283 bind proteins known as cyclophilin (Cyp) and FK506-binding protein, respectively, and the drug-protei

284 Bastadin, a novel modulator of the 12-kDa FK506 binding protein.RyR complex, increased [3H]ryanodi

285 rotein and includes rapamycin and the 12-kDa FK506 binding protein target 1.

286 dao-1, dao-8 and dao-9 are homologs of the FK506 binding proteins that interact with the mammalian

287 L. pneumophila Mip is a surface-exposed, FK506-binding protein that is needed for optimal infecti

288 FKBP38 is a member of the family of FK506-binding proteins that acts as an inhibitor of the

289 2-rapamycin-binding domain (FRB) and FKBP12 (FK506 binding protein), the interaction of hypoxia-induc

290 ther proteins, including calmodulin, FKBP12 (FK506-binding protein), the ryanodine receptor, and the

291 n blot analysis showed comparable binding of FK506-binding proteins to wild type and mutant receptors

292 Mutation of the immunophilin-like FK506-binding protein TWISTED DWARF1 (FKBP42/TWD1) cause

293 The role of slyD, which encodes a FK506 binding protein-type peptidyl-prolyl cis-trans iso

294 compounds with nanomolar affinities for the FK506 binding protein were rapidly discovered by tetheri

295 transactivation domains, each linked to the FK506 binding protein, were expressed in normal human sk

296 ation of receptor function by FKBP52 (52-kDa FK506-binding protein), which acts at a later stage of t

297 ay has been investigated in a variant of the FK506 binding protein with three additional residues at

298 Here, we assess the impact of FK506-binding protein with a molecular mass of approxima

299 lyses demonstrated CG17282 is a noncanonical FK506-binding protein with an inactive peptide prolyl-is

300 rtance of simultaneous interactions of AIPL1-FK506-binding protein with the prenyl moieties of PDE6 a